For its second fiscal quarter (ending June 30), iRadimed Corp (NASDAQ: IRMD) has reported E.P.S. of $0.39 compared to $0.33 a year ago. E.P.S. were $1.47 for the latest four quarters through June 30 versus $1.16 for the same period a year ago.
Recent Price Action
On 8/1/24, iRadimed Corp (NASDAQ: IRMD) stock declined modestly by -1.2%, closing at $46.15. Moreover, exceptionally high trading volume at 213% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -3.8% during the last week.
Current PriceTarget Research Rating
IRMD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
iRadimed has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. iRadimed has a slightly negative Power Rating of 35 and a very low Appreciation Score of 11, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment